Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16Thoracic 12Lymphoid 12Gastrointestinal 12Other hematologic neoplasm 11Plasma cell 9Dermatologic 8Sarcoma 7Gynecologic 7CNS 7Head & Neck 4Genitourinary 4Classical hematology 4Myeloid 3Other neoplasm 2Other 1

Conditions

Obesity 298Mucositis 116Neoplasms 108Breast Neoplasms 87Overweight 80Sexual Dysfunction, Physiological 74Polycystic Ovary Syndrome 71Dyspnea 48Motor Activity 46Constipation 45Head and Neck Neoplasms 42Weight Loss 36Prostatic Neoplasms 32Pain 29Stomatitis 26Endometrial Neoplasms 23Opioid-Induced Constipation 21Multiple Endocrine Neoplasia Type 1 20Diabetes Mellitus 20Lung Neoplasms 18Colorectal Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Sexual Dysfunctions, Psychological 15Depression 15Cardiovascular Diseases 15Anxiety Disorders 15Sedentary Behavior 13Insulin Resistance 13Infertility 13Cancer-related Fatigue 13

Interventions

Melphalan 1Fibroblast Growth Factor 7 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Drug-Related Side Effects and Adverse Reactions × Other × Clear all
NCT00482846 2014-04-15

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 1 Completed
38 enrolled
OtherPlasma cell

Multiple Myeloma, Mucositis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡